Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedNov 11, 2025
DataAggregated Company Financials
Companies1364
  • 7D4.5%
  • 3M14.1%
  • 1Y2.1%
  • YTD9.5%

In the last week, the Healthcare industry is up 3.9%, with Eli Lilly up 9.9%. In the same time, Humana was down 9.2%. Despite this gain, the industry's performance has been flat over the past year. Earnings are forecast to grow by 17% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 13 Nov 2025US$6.0tUS$3.2tUS$133.4b25.4x45.1x1.9x
Sat, 11 Oct 2025US$6.0tUS$3.1tUS$137.9b24.5x43.7x1.9x
Mon, 08 Sep 2025US$5.7tUS$3.1tUS$137.6b23.1x41.6x1.9x
Wed, 06 Aug 2025US$5.5tUS$3.1tUS$135.3b23.1x40.5x1.8x
Fri, 04 Jul 2025US$5.6tUS$3.0tUS$127.9b24.3x43.4x1.8x
Sun, 01 Jun 2025US$5.4tUS$3.0tUS$127.3b23.1x42.3x1.8x
Tue, 29 Apr 2025US$5.4tUS$2.7tUS$118.5b25.1x45.6x2x
Thu, 27 Mar 2025US$5.7tUS$2.6tUS$81.8b26.5x69.8x2.2x
Sat, 22 Feb 2025US$5.8tUS$2.6tUS$80.4b26.6x72.5x2.2x
Mon, 20 Jan 2025US$5.9tUS$2.9tUS$79.0b27.7x74.1x2x
Wed, 18 Dec 2024US$5.9tUS$2.9tUS$77.7b27.9x75.3x2x
Fri, 15 Nov 2024US$6.2tUS$2.9tUS$76.3b27.8x81.2x2.1x
Sun, 13 Oct 2024US$6.2tUS$2.8tUS$60.0b29.8x104x2.2x
Tue, 10 Sep 2024US$6.2tUS$2.8tUS$60.4b30.5x103.2x2.2x
Thu, 08 Aug 2024US$6.2tUS$2.9tUS$60.3b29.8x103.2x2.2x
Sat, 06 Jul 2024US$6.1tUS$2.8tUS$62.2b30.2x97.8x2.2x
Mon, 03 Jun 2024US$6.1tUS$2.8tUS$64.0b29.9x95.2x2.2x
Wed, 01 May 2024US$6.0tUS$2.8tUS$68.3b31.3x87.9x2.1x
Fri, 29 Mar 2024US$6.3tUS$2.8tUS$82.4b32.4x77x2.3x
Sun, 25 Feb 2024US$6.3tUS$2.8tUS$85.5b31.1x74x2.3x
Tue, 23 Jan 2024US$6.4tUS$2.8tUS$90.8b32.7x69.9x2.2x
Thu, 21 Dec 2023US$6.1tUS$2.8tUS$91.5b31.8x67.2x2.2x
Sat, 18 Nov 2023US$5.8tUS$2.8tUS$90.7b27.8x63.6x2x
Mon, 16 Oct 2023US$5.9tUS$2.8tUS$98.9b25.7x59.3x2.1x
Wed, 13 Sep 2023US$6.1tUS$2.8tUS$98.6b27.6x61.5x2.2x
Fri, 11 Aug 2023US$6.2tUS$2.8tUS$99.3b28.8x62.1x2.2x
Sun, 09 Jul 2023US$5.9tUS$2.7tUS$110.3b26x53.1x2.1x
Tue, 06 Jun 2023US$6.0tUS$2.7tUS$110.4b25.2x53.9x2.2x
Thu, 04 May 2023US$6.0tUS$2.7tUS$116.9b24.4x51.5x2.2x
Sat, 01 Apr 2023US$5.8tUS$2.5tUS$121.8b24.2x47.4x2.3x
Mon, 27 Feb 2023US$5.7tUS$2.5tUS$123.2b24.4x46.5x2.3x
Wed, 25 Jan 2023US$6.0tUS$2.5tUS$135.2b23.3x44.3x2.4x
Fri, 23 Dec 2022US$6.0tUS$2.5tUS$135.7b23.1x44.4x2.5x
Sun, 20 Nov 2022US$5.9tUS$2.4tUS$134.4b23.2x44.2x2.4x
Price to Earnings Ratio

44.2x


Total Market Cap: US$5.9tTotal Earnings: US$134.4bTotal Revenue: US$2.4tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65x202320242025
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 45.1x which is lower than its 3-year average PE of 65.0x.
  • The 3-year average PS ratio of 2.1x is higher than the industry's current PS ratio of 1.9x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have grown 9.2% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market0.42%
Healthcare4.47%
Pharma7.06%
Biotech4.28%
Medical Equipment4.22%
Life Sciences2.42%
Healthcare Services1.65%
Healthtech-4.30%
Industry PE
  • Investors are most optimistic about the Life Sciences industry even though it's trading below its 3-year average PE ratio of 61.6x.
    • Analysts are expecting annual earnings growth of 18.6%, which is higher than its past year's earnings decline of 5.1% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 23% over the next 5 years.
  • However this is lower than its past earnings growth rate of 52% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 13% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$1.02k9.9%
+US$82.3b		25.4%PE49.5x
ABBV AbbVieUS$233.237.6%
+US$29.1b		36.9%PE175.6x
JNJ Johnson & JohnsonUS$194.394.5%
+US$20.2b		26.9%PE18.6x
MRK MerckUS$91.458.4%
+US$17.5b		-7.2%PE11.9x
UNH UnitedHealth GroupUS$339.063.5%
+US$10.3b		-44.0%PE17.5x

Latest News

SGRY
US$15.86
Surgery Partners
7D
-27.8%
1Y
-37.8%
ABBV
US$233.23
AbbVie
7D
7.6%
1Y
36.9%
MRK
US$91.45
Merck
7D
8.4%
1Y
-7.2%
UNH
US$339.06
UnitedHealth Group
7D
3.5%
1Y
-44.0%
HIMS
US$39.02
Hims & Hers Health
7D
-10.8%
1Y
41.4%
TEM
US$71.10
Tempus AI
7D
-13.6%
1Y
4.4%

TEM: Revenue Will Accelerate With New Real-World Data Partnership

Analysts have raised their price target for Tempus AI from $82.50 to $87.17, citing shifts in expected growth and profitability as supporting factors for the updated valuation. What's in the News Tempus AI announced six new abstracts accepted for presentation at the SITC Annual Meeting 2025, highlighting advances in multi-omic algorithms and biomarkers for rare and advanced cancers (Product-Related Announcements).
AMGN
US$336.28
Amgen
7D
5.1%
1Y
11.6%
MCK
US$840.75
McKesson
7D
-0.4%
1Y
34.6%
DOCS
US$50.96
Doximity
7D
-20.4%
1Y
-3.6%
THC
US$199.99
Tenet Healthcare
7D
-4.1%
1Y
22.7%
JNJ
US$194.39
Johnson & Johnson
7D
4.5%
1Y
26.9%
LLY
US$1,017.78
Eli Lilly
7D
9.9%
1Y
25.4%

Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Nov 07
Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
BSX
US$104.13
Boston Scientific
7D
5.3%
1Y
17.3%

BSX: Shares Will See Momentum From Recent Acquisition And Execution Confidence

Boston Scientific's analyst price target has been increased modestly, with the consensus now reflecting a higher fair value in addition to ongoing confidence in robust growth prospects and recent business performance, as analysts cite solid quarterly results, improving guidance, and successful strategic acquisitions. Analyst Commentary Recent analyst research on Boston Scientific highlights both optimistic and cautious perspectives regarding the company's valuation, strategic moves, and long-term growth outlook.
HUM
US$240.48
Humana
7D
-9.2%
1Y
-16.9%
CAI
US$24.77
Caris Life Sciences
7D
-15.2%
1Y
n/a
ISRG
US$572.45
Intuitive Surgical
7D
4.4%
1Y
6.7%

Rising Demand And Cost Pressures Will Shape Robotic Surgery Outlook

The analyst price target for Intuitive Surgical has been raised from $573.55 to $594.29. Analysts cite strong third-quarter earnings, improving profit margins, and robust demand, despite ongoing pressures and competitive risks.